TWEAK antibody | MTW-1

100% Secure

Rat anti Mouse TWEAK

Product Type
Monoclonal Antibody
Product Code Applications Pack Size List Price Quantity
0.1 mg loader

Rat anti Mouse TWEAK antibody, clone MTW-1 recognizes mouse TWEAK (TNF-like weak inducer of apoptosis) a type II transmembrane TNF superfamily member. TWEAK binds to the TWEAK receptor FN14 (TWEAK-R) to weakly induce apoptosis in some cell types. It is involved in the induction of inflammatory cytokines. This cytokine also promotes proliferation and migration of endothelial cells and acts as a regulator of angiogenesis. TWEAK is expressed on a broad range of adult and foetal tissues. Rat anti Mouse TWEAK antibody, clone MTW-1 blocks ligand binding in vitro (Nakayama et al. 2003).

Product Details

Target Species
Product Form
Purified IgG - liquid
Purified IgG prepared by affinity chromatography
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
Approx. Protein Concentrations
IgG concentration 0.5mg/ml

Storage Information

Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
18 months from date of despatch.

More Information

O54907 Related reagents
Entrez Gene
Tnfsf12 Related reagents
GO Terms
GO:0005886 plasma membrane
GO:0001525 angiogenesis
GO:0006915 apoptosis
GO:0016021 integral to membrane
GO:0005125 cytokine activity
GO:0005164 tumor necrosis factor receptor binding
GO:0005615 extracellular space
GO:0006955 immune response
GO:0030154 cell differentiation
For research purposes only

Applications of TWEAK antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry 1/5 1/10
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.

Secondary Antibodies Available

Description Product Code Applications Pack Size List Price Quantity
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) STAR131A C E P WB 1 ml loader
Goat anti Rat IgG:Biotin (Mouse Adsorbed) STAR131B C E IF P WB 0.5 mg loader
Rabbit F(ab')2 anti Rat IgG:Dylight®800 STAR16D800GA F IF WB 0.1 mg loader
Rabbit F(ab')2 anti Rat IgG:FITC STAR17B F 1 mg loader
Rabbit F(ab')2 anti Rat IgG:HRP STAR21B C E P RE 1 mg loader
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) STAR69 F 0.5 ml loader
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) STAR71D800GA F IF WB 0.1 mg loader
Goat anti Rat IgG:HRP (Mouse Adsorbed) STAR72 C E P 0.5 mg loader
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) STAR73 F 0.5 ml loader

Product Specific References

Source Reference

  1. Nakayama M et al. (2003) Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies.
    Biochem Biophys Res Commun. 306 (4): 819-25.

References for TWEAK antibody

  1. Kamata K et al. (2006) Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis.
    J Immunol. 177 (9): 6433-9.
  2. Kaduka, Y. et al. (2005) TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage.
    Biochem Biophys Res Commun. 331 (2): 384-90.
  3. Zimmerman, Z. et al. (2005) Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Biol Blood Marrow Transplant. 11 (8): 576-86.
  4. Yoriki R et al. (2011) Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer.
    Exp Ther Med. 2 (1): 103-108.
  5. Frese-Schaper M et al. (2014) Influence of natural killer cells and perforin‑mediated cytolysis on the development of chemically induced lung cancer in A/J mice.
    Cancer Immunol Immunother. 63 (6): 571-80.